Javascript must be enabled to continue!
P-A2 Development of anti-Tat compound: MD Simulation of the Tat/Cyclin T1/CDK9 Complex Revealing the Hidden Catalytic Cavity within the CDK9 Molecule Upon Tat Binding
View through CrossRef
We applied molecular dynamics (MD) simulation to analyze the dynamic behavior of the Tat/CycT1/CDK9 tri-molecular complex and revealed the structural changes of P-TEFb upon Tat binding. We found that Tat could deliberately change the local flexibility of CycT1. Although the structural coordinates of the H1 and H2 helices did not substantially change, H1', H2', and H3' exhibited significant changes en masse. Consequently, the CycT1 residues involved in Tat binding, namely Tat-recognition residues (TRRs), lost their flexibility with the addition of Tat to P-TEFb. In addition, we clarified the structural variation of CDK9 in complex with CycT1 in the presence or absence of Tat. Interestingly, Tat addition significantly reduced the structural variability of the T-loop, thus consolidating the structural integrity of P-TEFb. Finally, we deciphered the formation of the hidden catalytic cavity of CDK9 upon Tat binding. MD simulation revealed that the PITALRE signature sequence of CDK9 flips the inactive kinase cavity of CDK9 into the active form by connecting with Thr186, which is crucial for its activity, thus presumably recruiting the substrate peptide such as the C-terminal domain of RNA pol II. These findings provide vital information for the development of effective novel anti-HIV drugs with CDK9 catalytiactivity as the target.
Ovid Technologies (Wolters Kluwer Health)
Title: P-A2 Development of anti-Tat compound: MD Simulation of the Tat/Cyclin T1/CDK9 Complex Revealing the Hidden Catalytic Cavity within the CDK9 Molecule Upon Tat Binding
Description:
We applied molecular dynamics (MD) simulation to analyze the dynamic behavior of the Tat/CycT1/CDK9 tri-molecular complex and revealed the structural changes of P-TEFb upon Tat binding.
We found that Tat could deliberately change the local flexibility of CycT1.
Although the structural coordinates of the H1 and H2 helices did not substantially change, H1', H2', and H3' exhibited significant changes en masse.
Consequently, the CycT1 residues involved in Tat binding, namely Tat-recognition residues (TRRs), lost their flexibility with the addition of Tat to P-TEFb.
In addition, we clarified the structural variation of CDK9 in complex with CycT1 in the presence or absence of Tat.
Interestingly, Tat addition significantly reduced the structural variability of the T-loop, thus consolidating the structural integrity of P-TEFb.
Finally, we deciphered the formation of the hidden catalytic cavity of CDK9 upon Tat binding.
MD simulation revealed that the PITALRE signature sequence of CDK9 flips the inactive kinase cavity of CDK9 into the active form by connecting with Thr186, which is crucial for its activity, thus presumably recruiting the substrate peptide such as the C-terminal domain of RNA pol II.
These findings provide vital information for the development of effective novel anti-HIV drugs with CDK9 catalytiactivity as the target.
Related Results
Abstract 2995: CDK9 phosphorylates BRG1 chromatin remodeler
Abstract 2995: CDK9 phosphorylates BRG1 chromatin remodeler
Abstract
Cyclin-dependent kinase 9 (CDK9) belongs to the class of CDKs involved in transcription regulation along with CDK7, 8, 10-13. Earlier works have established...
Abstract 2958: Cyclin D1 regulates the ARF and INK4a promoters
Abstract 2958: Cyclin D1 regulates the ARF and INK4a promoters
Abstract
Cyclin D1 is a member of cyclin protein family, which drives the cell cycle transition from G1 to S phase. The cyclin D1 protein is overexpressed in ∼50% of...
Abstract 5988: A non-canonical CDK9 complex mediates endocycling in polyaneuploid cancer cell (PACC) state
Abstract 5988: A non-canonical CDK9 complex mediates endocycling in polyaneuploid cancer cell (PACC) state
Abstract
Once prostate cancer has spread from its primary site, treatment is limited to systemically administered therapy. While tumors initially respond to these th...
HIV-1 Tat amino acid residues that influence Tat-TAR binding affinity: a scoping review
HIV-1 Tat amino acid residues that influence Tat-TAR binding affinity: a scoping review
Abstract
HIV-1 remains a global health concern and to date, nearly 38 million people are living with HIV. The complexity of HIV-1 pathogenesis and its subsequent ...
Abstract 1626: CDK9 inhibition enhances apoptosis of TP53 mutated AML when combined with standard chemotherapy
Abstract 1626: CDK9 inhibition enhances apoptosis of TP53 mutated AML when combined with standard chemotherapy
Abstract
Background:
The prognosis of patients with acute myeloid leukemia (AML) remains poor for those with mutations or deleti...
CDK9 is dispensable for YAP‐driven hepatoblastoma development
CDK9 is dispensable for YAP‐driven hepatoblastoma development
AbstractBackgroundHepatoblastoma (HB) is the most common pediatric liver malignancy, occurring mainly during the first 4 years of life. Recent studies unraveled the frequent, coord...
CDK9: Therapeutic Perspective in HCC Therapy
CDK9: Therapeutic Perspective in HCC Therapy
CDK9 is an important cell-cycle control enzyme essential in transcription, elongation, and
mRNA maturation. Overexpression of CDK9 has been reported in several diseases, including ...
Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies
Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies
Abstract
Cyclin-dependent kinase 9 (CDK9) is a serine/threonine kinase that regulates elongation of transcription through phosphorylation of RNA polymerase II at ser...

